SEC EDGARAUG 41 min read$IRTC

Patterson Chad sold $331K of IRTC

Patterson Chad (CHIEF COMM & PRODUCT OFFICER) sold 2,712 shares of iRhythm Holdings, Inc. (IRTC) at $122.12 ($0.33M total) on 2026-08-03.

Original reporting

SEC EDGAR · Patterson Chad

Published Aug 4, 2026, 8:01 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 4, 2026, 8:06 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$IRTC

Neutral

medium confidence

Mentioned

$IRTC

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$IRTCNeutralLow

Why it matters

This provides a fresh datapoint on insider behavior but does not introduce new fundamentals, guidance, or legal/regulatory developments.

Market read

Traders may monitor insider selling as a sentiment input, but the filing alone is unlikely to drive a durable repricing without accompanying fundamental news.

What to watch

The article does not state whether the sale was part of compensation, tax withholding, or other pre-planned arrangements; also, insider sales can be scheduled around personal needs rather than company outlook.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04, sale dated 2026-08-03

Background

The article is a Form 4 insider transaction disclosure for iRhythm Holdings, Inc.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$IRTCNeutralMedium confidence

Context

iRhythm Holdings insider Patterson Chad sold 2,712 shares at $122.1209 on 2026-08-03, totaling $331,191.88.

Expected impact

Likely limited near-term impact; any effect would be small and sentiment-driven.

Evidence & confidence

Form 4 shows an officer sale, but the filing provides no new business information, guidance, or regulatory/legal development. Absence of a 10b5-1 plan can raise interpretive noise, yet insider sales are often non-informational.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide signal in the text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be purely liquidity or tax-related, especially since the filing does not indicate any operational or financial deterioration.

Key entities

issuer
iRhythm Holdings, Inc.
Subject of the Form 4 insider transaction disclosure.
insider
Patterson Chad
Chief Commercial and Product Officer who sold shares.

Read at source ← All news

SEP 14

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min

SEP 4

$IRTCMed

Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?

iRhythm Holdings (IRTC) reported Q2 2026 revenues of $224.2M, up 20.1% YoY, and raised full-year guidance to $880-$890M. Gross margin expanded to 72.8%, and adjusted EBITDA grew over 1,000 bps YoY. However, risks include reimbursement uncertainties, execution challenges, and an unresolved FDA warning letter.

tradingview.com3 min

SEP 4

$PODDMedAI 8/10

Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.

finance.yahoo.com3 min

SEP 3

$IRTCMed

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.

finance.yahoo.com2 min

AUG 16

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.

aol.com6 min

AUG 11